Clinical Trial Update: Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever [Phase 2]

View source ↗

Summary

Phase 2a immunogenicity study of a Hantaan/Puumala virus DNA vaccine for prevention of Hemorrhagic Fever with Renal Syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhagic Fever with Renal Syndrome

Drugs mentioned

• Hantaan/Puumala virus DNA vaccine

Snippet

Sponsor: U.S. Army Medical Research and Development Command | Conditions: Hemorrhagic Fever With Renal Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2020-12-01